DIAGNOSTIC FEATURES OF HYPERCOAGULATION SYNDROME IN TYPE 2 DIABETES: CLINICAL LAB INSIGHTS

https://doi.org/10.5281/zenodo.10265201

Omonov A.A
Tashkent Medical Academy

Abstract: *Patients with Type 2 Diabetes Mellitus (T2DM) are at an increased risk of developing hypercoagulation syndrome, a condition where blood clots form excessively and abnormally. Clinical laboratory diagnostics play a vital role in identifying and managing this syndrome in individuals with T2DM. Here are the key features of clinical laboratory diagnostics concerning hypercoagulation syndrome in these patients:*

Keywords: *Diabetes Mellitus, hypercoagulation, syndrome, D-Dimer*

COAGULATION PROFILE:

Laboratory tests, including Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), are conducted to assess the clotting function of the blood. Elevated PT and aPTT levels may indicate impaired coagulation factors, suggesting an increased risk of abnormal blood clot formation.

D-DIMER LEVELS:

D-Dimer is a protein fragment present in the blood after a blood clot dissolves. Elevated D-Dimer levels indicate increased clot formation and breakdown in the body. In patients with T2DM, monitoring D-Dimer levels is crucial as it helps in the early detection of hypercoagulation.

PLATELET COUNT:

Platelets are essential components in blood clot formation. Abnormal platelet counts, either too high or too low, can contribute to hypercoagulation. Regular monitoring of platelet counts through laboratory tests provides valuable information about a patient's clotting risk.

FIBRINOGEN LEVELS:

Fibrinogen is a protein that helps in the formation of blood clots. High fibrinogen levels can indicate an increased tendency for blood clotting. Patients with T2DM are often screened for fibrinogen levels to assess their risk of hypercoagulation.

Anticoagulant Proteins:

Tests measuring anticoagulant proteins such as Protein C and Protein S provide insights into the body's natural anticoagulant mechanisms. Deficiencies in these proteins can lead to an imbalance in the coagulation process, increasing the risk of abnormal clot formation.

GENETIC TESTS:

Genetic testing may be conducted to identify inherited conditions that predispose individuals to hypercoagulation. Certain genetic mutations, such as Factor V Leiden mutation, significantly increase the risk of blood clots and are more prevalent in patients with diabetes.

INFLAMMATORY MARKERS:

Chronic inflammation is common in patients with T2DM and can contribute to hypercoagulation. Laboratory tests measuring inflammatory markers like C-reactive protein (CRP) provide insights into the inflammatory status, aiding in the assessment of the overall hypercoagulation risk.

In summary, clinical laboratory diagnostics play a crucial role in identifying hypercoagulation syndrome in patients with Type 2 Diabetes Mellitus. Regular monitoring of coagulation profiles, D-Dimer levels, platelet counts, fibrinogen levels, anticoagulant proteins, genetic factors, and inflammatory markers is essential for early detection, risk assessment, and effective management of hypercoagulation in individuals with diabetes, ultimately reducing the risk of complications associated with abnormal blood clot formation.

REFERENCES:

2. Abduvaliev A.R., Inoyatova F.Kh., Mirkomilov E.M. A method of inhibiting t-helper 2 cells to prevent lung fibrosis that develops as a result of atypical pneumonia in COVID-19 // Proceeding of Global Congress of Contemporary Study- A Multidisciplinary International Scientific Conference Hosted from Pune, M.S. India.- P.182-187. www.econferenceglobe.com.

3. Sushentseva N. N., Popov O. S., Apalko S. V. et al. Biobank COVID-19: features of the cytokine profile / / Cardiovascular therapy and prevention. 2020, vol.19 (6), pp. 191-195..191-195.

4. Xia H., Bodempudi V., Benyumov A. et al. Identification of a celloforigin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis Am. J. Pathol. 2014;184: 1369–1383.

5. Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis: the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med. 2013; 19: 460–465.

6. Thorax. The pulmonary physician in critical care 6: The pathogenesis of ALI/ARDS/ G.J.Bellingan // Thorax 2002 Jun; 57(6):540-6./ doi:10.1136/ thorax. 57.6.540.

7. Ниёзова, Ш. С., Турсунов, Д. Х., Алимов, С. М., Ахматова, К. А., & Султонова, Д. Ш. (2023). Covid-19 билан касалланган беморлар қон зардобида оқсил алмашинуви кўрсаткичларининг тахлили (Doctoral dissertation, KLINIK LABORATOR DIAGNOSTIKADA INNOVATSION TEXNOLOGIYALARDAN FOYDALANISH, MUAMMOLAR VA YECHIMLAR).